These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 7093867)

  • 1. Steady-state plasma levels of salicylate in patients with rheumatoid arthritis: effects of dosing interval and tablet strength.
    Keystone EC; Paton TW; Littlejohn G; Verdejo A; Piper S; Wright LA; Goldsmith CH
    Can Med Assoc J; 1982 Aug; 127(4):283-6. PubMed ID: 7093867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin dosing using 15 grain enteric coated tablets.
    Pollet S; White RH; Jang H; Yim CW; Feigal D
    J Rheumatol; 1985 Apr; 12(2):337-42. PubMed ID: 4032405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twice-daily dosing of enteric-coated aspirin in patients with rheumatic diseases.
    Bensen WG; Laskin CA; Paton TW; Little HA; Fam AG
    J Rheumatol; 1979; 6(3):351-9. PubMed ID: 314982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analgesics; the use of aspirin in dogs; effects of tablet type and food intake on plasma salicylate level].
    Nap RC; Breen DJ; Lam TJ; Peters IO; Willemsen A; De Bruyne JJ
    Tijdschr Diergeneeskd; 1993 Jul; 118(13):439-42. PubMed ID: 8346511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double blind comparison of piroxicam and enteric coated ASA in rheumatoid arthritis. A Cooperative Multicenter Canadian trial.
    J Rheumatol; 1985 Feb; 12(1):68-77. PubMed ID: 3884806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of omeprazole with enteric-coated salicylate tablets.
    Nefesoglu FZ; Ayanoglu-Dülger G; Ulusoy NB; Imeryüz N
    Int J Clin Pharmacol Ther; 1998 Oct; 36(10):549-53. PubMed ID: 9799060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of three slow-release acetylsalicylic acid preparations in rheumatoid arthritis.
    Martio J; Kahela P
    Scand J Rheumatol; 1983; 12(3):305-9. PubMed ID: 6623020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A strategy for reaching therapeutic salicylate levels in patients with rheumatoid arthritis using standardized dosing regimens.
    Furst DE; Blocka K; Cassell S; Dromgoole S; Harris ER; Hirschberg JM; Josephson N; Rupp PA; Paulus HE; Trimble RB
    J Rheumatol; 1987 Apr; 14(2):342-7. PubMed ID: 3599003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatal iatrogenic salicylate intoxication in a long-term user of enteric-coated aspirin.
    Shkrum MJ; Gay RM; Hudson P
    Arch Pathol Lab Med; 1989 Jan; 113(1):89-90. PubMed ID: 2910232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dosage effect of enteric-coated ASA on serum salicylate levels.
    Woodbury JF; Ahmad S
    N S Med Bull; 1973 Jun; 52(3):123-6. PubMed ID: 4584430
    [No Abstract]   [Full Text] [Related]  

  • 11. Plasma salicylate levels in rheumatoid arthritis produced by four different salicylate preparations.
    Armstrong BK; Ukich AW; Goatcher PM
    Med J Aust; 1970 Jul; 2(4):181-3. PubMed ID: 4917130
    [No Abstract]   [Full Text] [Related]  

  • 12. [Enteric aspirin tablets and the salicylate concentration in the plasma in the morning].
    Laine V; Strandman D; Tikkanen R
    Lakartidningen; 1968 Sep; 65(39):3832-7 passim. PubMed ID: 5741894
    [No Abstract]   [Full Text] [Related]  

  • 13. Enteric-coated pelletized aspirin. Gastrointestinal blood loss and bioavailability.
    Portek I; Graham G; Fleming A
    Med J Aust; 1981 Jul; 2(1):39-40. PubMed ID: 6974303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin kinetics and inhibition of platelet thromboxane generation-relevance for a solution of the "aspirin dilemma".
    Cerletti C; Latini R; Del Maschio A; Galletti F; Dejana E; de Gaetano G
    Thromb Haemost; 1985 Jun; 53(3):415-8. PubMed ID: 4049312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative bioavailability of aspirin from buffered, enteric-coated and plain preparations.
    Latini R; Cerletti C; de Gaetano G; Dejana E; Galletti F; Urso R; Marzot M
    Int J Clin Pharmacol Ther Toxicol; 1986 Jun; 24(6):313-8. PubMed ID: 3733281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical study on a new acetylsalicylic acid/paracetamol preparation with gastric acid resistant coating (Safapryn), and on two various phenylbutazone dosages in patients with primary chronic polyarthritis as based on a new evaluation method].
    Brooks PM; Walker JJ; Lee P; Bell AM; Buchanan WW; Fowler PD; Anderson JA
    Z Rheumatol; 1975; 34(9-10):350-65. PubMed ID: 1106038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of different aspirin formulations on platelet aggregation times and on plasma salicylate concentrations.
    Schwertner HA; McGlasson D; Christopher M; Bush AC
    Thromb Res; 2006; 118(4):529-34. PubMed ID: 16298420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steady-state pharmacokinetics of enteric-coated naproxen tablets compared with standard naproxen tablets.
    Jung D; Schwartz KE
    Clin Ther; 1994; 16(6):923-9. PubMed ID: 7697688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epilim chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers.
    Roberts D; Easter D; O'Bryan-Tear G
    Biopharm Drug Dispos; 1996 Mar; 17(2):175-82. PubMed ID: 8907724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative analysis of two dosing strategies of flurbiprofen in rheumatoid arthritis: an application of sequential trial design.
    Bellamy N; Kreeft JH
    Clin Invest Med; 1988 Dec; 11(6):441-5. PubMed ID: 3067924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.